전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 갱신 권장 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,403 programs

데이터 갱신 주기입니다. 갱신 대기 7,609개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleAIDS Malignancy ConsortiumPhase 2

yttrium Y 90 ibritumomab tiuxetan (yttrium Y 90 ibritumomab tiuxetan)

AIDS-related Lymphoma; Adult Non-Hodgkin's Lymphoma · AIDS-related Lymphoma

#AIDS-relatedLymphoma#Antibody#Phase2#monoclonal-antibody#AdultNon-HodgkinsLymphoma+1
Trials 1Status Discontinued
AntibodyLimited DatastalePartner Therapeutics, Inc.Phase 2

MCLA-128 (zenocutuzumab, zenocutuzumab (MCLA-128))

Solid Tumours Harboring NRG1 Fusion; NSCLC Harboring NRG1 Fusion · Solid Tumours Harboring NRG1 Fusion

#SolidTumoursHarboringNRG1Fusion#Antibody#Phase2#monoclonal-antibody#NSCLCHarboringNRG1Fusion+1
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

BHP01 (α-PD-L1/4-1BB DLL3 CAR-T, α-PD-L1/4-1BB DLL3 CAR-T (BHP01))

Small Cell Lung Cancer Extensive Stage · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting

121 / 121 pages

← PreviousNext →